More recently, researchers have explored these effects and other therapeutic uses, such as in attention-deficit hyperactivity ...

During a Case-Based Roundtable® event, Christopher Maisel, MD, discussed the data behind loncastuximab and whether ...

The FDA approved Ocrevus Zunovo, a subcutaneous formulation of Ocrevus, for adults with relapsing forms of MS and PPMS ...

AbbVie (NYSE: ABBV) today announced that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending the marketing ...

Median duration of response reaches 7.4 months with combination treatment in patients with aggressive form of disease ...